Want to see ES:CBAV full AI Analyst Report?
CBAV Stock Chart & Stats
€47.30
€0.20(0.61%)
At close: 4:00 PM EST
€47.30
€0.20(0.61%)
Day’s Range― - ―
52-Week Range€40.10 - €61.80
Previous CloseN/A
Volume285.00
Average Volume (3M)2.20K
Market Cap
€939.08M
Enterprise Value€894.31M
Total Cash (Recent Filing)€64.83M
Total Debt (Recent Filing)€68.15M
Price to Earnings (P/E)21.4
Beta0.56
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.31%
Share Statistics
EPS (TTM)2.69
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio2.92
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)€330.20M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryMulti-year organic revenue growth with a marked TTM acceleration indicates expanding patient volumes and stronger clinic utilization. Durable top-line momentum supports scale advantages in purchasing, fixed-cost absorption and continued investment in clinical capacity over the next 2–6 months.
Sustained ProfitabilityConsistently high operating and EBITDA margins reflect efficient clinic operations and favorable procedure mix. Durable margins support cash flow generation, enable reinvestment in technology and staffing, and provide resilience to moderate volume swings across the network over the medium term.
Strong Cash GenerationOCF reliably above net income signals high earnings quality and real cash conversion from clinic services. Positive free cash flow, despite volatility, funds capex, clinic upgrades and shareholder returns while preserving financial flexibility for measured expansion or debt paydown.
Bears Say
Leverage Remains MeaningfulAlthough leverage has improved, absolute debt levels have not declined materially, leaving balance sheet sensitivity to slower cash flow or cyclical dips. Meaningful leverage can restrict strategic flexibility for M&A, larger capital projects or rapid share buybacks if earnings soften.
Free Cash Flow VolatilityVariability in FCF reflects capex timing and reinvestment in clinics; this unpredictability complicates planning for dividends, debt reduction or expansion. Persistent FCF volatility could constrain consistent return of capital or slow opportunistic investments during downturns.
Exposure To Elective ProceduresConcentration in elective ophthalmic procedures makes revenue sensitive to consumer demand, macro conditions and competitive pricing. Structural reliance on out-of-pocket or partially reimbursed services increases cyclicality and geographic reimbursement risk over the medium term.
Clinica Baviera News
CBAV FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest stock price was €40.10 and its highest was €61.80 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €939.08M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Jul 28, 2026 which is in 27 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Mar 04, 2026. The company reported €0.813 earnings per share for the quarter, beating the consensus estimate of N/A by €0.813.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Overvalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA pays a Annually dividend of €1.568 which represents an annual dividend yield of 3.31%. See more information on Clinica Baviera, SA dividends here
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.813 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.788%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in ES:CBAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.
Technical Analysis
Options Prices
Currently, No data available
---